Skip to content

HPLC Purity vs Mass Spec Identity: What '99% Pure' Really Means on a Research Peptide

Last updated:

Short answer: On a research peptide certificate of analysis (COA), "99% pure" almost always means the target peptide produced 99% of the total UV peak area in a reversed-phase HPLC chromatogram, relative to the related impurities that method could detect. It does not mean the vial is 99% peptide by weight, and it does not prove the peptide is the right molecule. Identity is a separate result, usually from mass spectrometry, which checks that the measured molecular weight matches the expected sequence.

Key definitions

  • HPLC purity: The target peak's area as a percentage of all integrated peak area in a UV chromatogram, under one specific method.
  • Mass spectrometry (MS) identity: A check that the observed molecular weight matches the theoretical weight of the intended sequence, reported as "conforms" or "does not conform."
  • Net peptide content: The fraction of a sample's total weight that is peptide, after water, counter-ions and other non-peptide material.
  • Related impurities: Peptide species that differ slightly from the target, such as deletion sequences, oxidized forms or stereoisomers.
  • Counter-ion: A charged molecule, typically trifluoroacetate (TFA) or acetate, paired with charged groups on the peptide in the lyophilized powder.

What HPLC peptide purity actually measures

Most peptide purity testing uses reversed-phase high-performance liquid chromatography (RP-HPLC). The sample is loaded onto a hydrophobic column, often C18, and eluted with a water and acetonitrile gradient containing an acid modifier such as TFA. A UV detector set near 210 to 220 nm, where the peptide bond absorbs, records each peak.

Purity is the target peak area divided by the sum of all integrated peak areas, multiplied by 100. A result of 99.0% means 1.0% of the detected UV signal came from other species. It is a ratio of signals, not a weighed quantity, so column chemistry, gradient, wavelength and integration settings can all shift it. ICH Q6B, written for biotechnological products rather than synthetic peptides, states the principle directly: absolute purity is difficult to determine and results are method-dependent.

The impurities HPLC is designed to find

Each step of solid-phase synthesis can leave a small fraction of off-target product. A peer-reviewed review of peptide-related impurities (D'Hondt et al., 2014) describes common types, including:

  • Deletion and truncated sequences, where one or more residues are missing.
  • Insertion sequences, where a residue was added twice.
  • Incomplete deprotection, where a side-chain protecting group remains.
  • Diastereomers from racemization, where an amino acid converted from the L to the D form.
  • Oxidation (often at methionine or tryptophan) and deamidation (at asparagine or glutamine).

A USP expert panel on peptide analytics, writing in Pharmaceutical Technology, notes that the method should distinguish the peptide from its closely related impurities and recommends orthogonal separation mechanisms to confirm it does.

What mass spectrometry confirms about peptide identity

Mass spectrometry answers a different question: is this the right molecule? Electrospray ionization (ESI) or MALDI turns peptide molecules into ions, and the instrument measures their mass-to-charge ratio (m/z). ESI spectra often show several charge states, such as [M+2H]2+, which software converts back to one molecular mass.

That mass is compared with the theoretical value calculated from the sequence. The same USP panel article states the monoisotopic mass should fall within plus or minus 1.0 mass unit of theoretical for identity. A mismatch points to the wrong sequence, an unexpected modification or an adduct.

What mass spec cannot tell you

  • Isomers. Leucine and isoleucine share a mass, as do the L and D forms of any amino acid.
  • Purity. Species ionize with different efficiency, so MS peak heights are not a purity percentage.
  • Content by weight. MS does not measure water, counter-ions or net peptide content.

Coupled as LC-MS, the two techniques assign a mass to each HPLC peak.

Peptide purity testing methods compared

TestQuestion it answersTypical COA outputWhat it cannot tell you
RP-HPLC with UV detectionHow much of the UV-detected peptide material is the target?Purity as % peak area, often with chromatogram and largest single impurityIdentity; content by weight; co-eluting or weakly absorbing impurities
Mass spectrometry (ESI or MALDI)Does the molecular weight match the intended sequence?Observed vs theoretical mass; conforms or does not conformPurity percentage; isomers such as Leu/Ile or D/L forms; content by weight
Net peptide content (amino acid or nitrogen analysis)What fraction of the powder's weight is peptide?Peptide content as % w/wWhether the peptide is the correct sequence, or how pure it is
Water content (Karl Fischer)How much moisture is in the powder?Water as % w/wAnything about the peptide itself
Counter-ion analysis (ion chromatography or HPLC)How much TFA or acetate is present?Counter-ion as % w/wIdentity or purity of the peptide

Why "identity purity" is a muddled phrase

Some product pages merge the two results into one line, such as "identity purity: 99%." That phrase does not describe a recognized test. Identity is pass or fail: the observed mass matches the theoretical mass within a stated tolerance or it does not. Purity is a percentage produced by a separation method. ICH Q2(R2), the reference framework for validating analytical procedures, treats identification, impurity testing and assay as distinct purposes, each validated on its own terms.

When you see the combined phrase, ask which method produced the percentage and where the mass result is.

Purity vs net peptide content: why a vial is not 100% peptide

A lyophilized peptide is a salt, not a pure substance. Peptides are typically cleaved and purified using TFA, and positively charged groups (the N-terminus plus arginine, lysine and histidine side chains) retain TFA or, after ion exchange, acetate counter-ions. Many peptides are also hygroscopic and absorb water.

None of that material is counted in HPLC purity. Water is transparent at the wavelengths used, and counter-ions either elute near the solvent front, outside integration, or cannot be distinguished from acid in the mobile phase. A peptide can therefore be 99% pure by HPLC while only part of the powder's weight is peptide.

Net peptide content captures that gap. It is usually measured by quantitative amino acid analysis, which hydrolyzes the peptide and quantifies each amino acid, or by nitrogen analysis. Purity describes the composition of the peptide material; content describes how much of the powder is peptide at all.

What HPLC can miss

  • Co-eluting impurities, such as some diastereomers hidden under the main peak.
  • Uneven UV response, since area percent assumes similar absorbance for target and impurities.
  • Material outside the gradient window, from very polar or very hydrophobic species.
  • Non-peptide content: water, counter-ions, inorganic salts and most residual solvents.

How to read the numbers: a worked example

The COA below is hypothetical. Its values are illustrative only and do not describe any Lumen product or lot.

TestMethodSpecificationResult
IdentityESI-MSMonoisotopic mass 1,200.60 Da, plus or minus 1.0 DaObserved 1,200.61 Da (from [M+2H]2+ at m/z 601.31); conforms
PurityRP-HPLC, UV 214 nmNot less than 98.0%99.1%
Largest single impurityRP-HPLC, UV 214 nmNot more than 0.5%0.4%
Net peptide contentAmino acid analysisReport result78.0%
Water contentKarl FischerReport result7.0%
Acetate contentIon chromatographyReport result14.0%
  1. Identity first. The observed mass is 0.01 Da from theoretical, well inside the 1.0 Da tolerance. That confirms the expected sequence mass, though not the absence of an isomer.
  2. Purity next. 99.1% of the UV peak area at 214 nm belongs to the target. The other 0.9% is related impurities, the largest at 0.4%.
  3. Then content. Net peptide content (78.0%), water (7.0%) and acetate (14.0%) account for 99.0% of the powder's weight. The remaining 1.0% is unassigned material or measurement uncertainty.
  4. Finally, combine. In a vial holding 10 mg of gross powder, about 7.80 mg is peptide material (10 x 0.780). Multiplying by HPLC purity gives about 7.73 mg of target sequence (7.80 x 0.991). Treat that as an approximation, because related impurities sit within net peptide content.

Also confirm the lot number matches the vial, the laboratory is named, and the chromatogram and spectrum are attached. Lumen publishes a third-party COA for every lot in its COA library.

Some compounds need an extra step. For a metal complex such as GHK-Cu, check whether the reported mass refers to the free tripeptide or the copper complex, since a spectrum can show either. The same reading order applies across the Lumen research catalog.

FAQ

Does 99% HPLC purity mean the vial is 99% peptide by weight?

No. HPLC purity is a share of UV peak area among detected peptide species. Water, counter-ions and salts are excluded, so the peptide's share of the powder's weight is reported separately as net peptide content.

Can a peptide pass HPLC purity and fail identity?

Yes. A synthesis that produced the wrong sequence can still yield one clean, dominant peak. HPLC purity would look high while mass spectrometry would show a molecular weight that does not match.

Why do COAs report both HPLC and mass spec results?

They answer different questions. HPLC measures how much of the peptide material is the target relative to related impurities. Mass spectrometry confirms the target's molecular weight. Neither substitutes for the other.

What should a complete peptide COA include?

The lot number, testing laboratory and date, HPLC purity with method details and chromatogram, and MS identity with theoretical and observed mass. Net peptide content, water and counter-ion results add the weight-based picture. Lumen's reports are in the COA library.

What impurities can HPLC miss?

Co-eluting impurities such as some diastereomers, weakly absorbing species, material outside the gradient window, and all non-peptide content. Orthogonal HPLC methods and LC-MS reduce these blind spots.

Research use only

All Lumen Peptides products are sold strictly for in-vitro laboratory research. They are not for human or veterinary use and are not intended to diagnose, treat, cure or prevent any disease. This article describes analytical methods for educational purposes only.

References

  1. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures: Guidance for Industry. March 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures
  2. U.S. Food and Drug Administration / ICH. Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. August 1999. Cited for general principles; its scope excludes synthetic peptides. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6b-specifications-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products
  3. Swietlow A, Verlander M, Gregg B, et al. (USP Therapeutic Peptides Expert Panel). "Control Strategies for Synthetic Therapeutic Peptide APIs, Part I: Analytical Consideration." Pharmaceutical Technology 38(3), March 2014. https://www.pharmtech.com/view/control-strategies-synthetic-therapeutic-peptide-apis-part-i-analytical-consideration-0
  4. D'Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. "Related impurities in peptide medicines." Journal of Pharmaceutical and Biomedical Analysis 101 (2014): 2-30. https://doi.org/10.1016/j.jpba.2014.06.012

All research articles